Skip to main content

Congratulations to our new PhD, Jeffrey DiBerto!

February 3, 2023

Dr. DiBerto successfully defended his thesis, “Discovery Campaigns for Pharmacologically Unique Agonists at the Mu-Opioid and 5-Hydroxytryptamine 2A Receptors on Jan. 19.”

Scientists Elucidate How DREADD Technology Highjacks Neuronal Activity

December 8, 2022

The Bryan Roth lab got some nice press for their recent Nature paper, revealing structural details of his chemogenetic technology called DREADD – designer receptors exclusively activated by designer drugs – that recognize drug-like but physiologically inert compounds. Postdoc Shicheng Zhang, PhD, led this research published in Nature.